VALIDATING UBC9 AS A MOLECULAR TARGET TO DEVELOP A THERAPY FOR ALL FORMS OF ALS

$687,779FY2018Department of the ArmyDOD

J.David Gladstone Institutes

Investigators

VALIDATING UBC9 AS A MOLECULAR TARGET TO DEVELOP A THERAPY FOR ALL FORMS OF ALS · GrantIndex